Psychoactive drug MDMA
Keywords:
MDMA, Ecstasy, PTSD, Dopamine, Serotonin.Abstract
Background: 3,4-Methylenedioxymethamphetamine (MDMA; ecstasy, molly) is a synthetic psychoactive drug that produces increased empathy, emotional connection, and heightened sensory percepstion. After early use as an adjunct to psychotherapy and widespread recreational use, it was placed under strict legal control in many countries. Recent research has renewed interest in its therapeutic potential, particularly for post-traumatic stress disorder (PTSD).
Objective: To review the pharmacological effects of MDMA, its historical and cultural significance, the current evidence for MDMA-assisted therapy, and the debate over its legal status.
Methods: Narrative review of the pharmacological, historical, clinical, and policy literature on MDMA, with emphasis on clinical trials of MDMA-assisted psychotherapy for PTSD and on regulatory and legal frameworks across jurisdictions.
Results: MDMA acts mainly by releasing serotonin and inhibiting its reuptake, with lesser effects on noradrenaline and dopamine and increased oxytocin signalling. Acute risks include hyperthermia, hyponatraemia, and cardiovascular strain, and heavy or repeated use raises concern about serotonergic neurotoxicity. Clinical trials report reductions in PTSD symptom severity when MDMA is combined with structured psychotherapy. Limitations include functional unblinding, expectancy effects, variable therapist conduct, and limited long-term safety data. Legal and regulatory approaches differ considerably between countries.
Conclusions: MDMA-assisted therapy shows therapeutic promise, but larger and more rigorous trials, standardised treatment protocols, and long-term safety monitoring are needed. Drug policy should be guided by evidence while still addressing the harms of unsupervised recreational use.
References
Forsyth, A.J.M., A quantitative exploration of dance drug use: the new pattern of drug use of the 1990s. 1997, University of Glasgow.
Balli, R., How to Cure a Gabba. Dancecult: Journal of Electronic Dance Music Culture, 2014. 6(2).
St John, G., Technomad. 2009: Berghahn.
Lieberman, M.D., & McGlinchey, E. M. , Neurobiological substrates of social anxiety disorder. a review of functional neuroimaging studies. Depression and Anxiety: p. 1013-1025.
McCann UD, R.G., Madras BK, Serotonin and dopamine release from striatum after oral administration of MDMA in the conscious rat Psychopharmacology. (https://www.ncbi.n lm.nih.gov/pmc/articles/PMC3137209): p. 70-165
Spierling H, M.A., Zimmermann T, et al, Increased norepinephrine and dopamine release in the human brain after oral MDMA administration as measured by positron emission tomography (PET) Mol Psychiatry. (https://pubmed.ncbi.nlm.nih.gov/16220332): p. 244-51.
Green AR, M.A., Elliott JM, et al, Dose-related effects of MDMA on human therm oregulation. J Psychopharmacology. (https://pubmed.ncbi.nlm.nih.gov/21924843): p. 249-58.
Frezza M, N.D., Sinclair JD, Effects of (+/-)-3,4-methylenedioxymethamphetamine (MDMA) on human rectal temperature and sweating: a double-blind, placebo-controlled study. Psychopharmacology Reyad, A.A., et al., Bruxism and psychotropic medications. Progress in neurology and psychiatry, 2020. 24(1): p. 31-35.
Chobanian, A.V., et al., Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. hypertension, 2003. 42(6): p. 1206-1252.
McCann, U.D., & Ricaurte, G. A, MDA, MDMA and the serotonin system. a comprehensive review. Psychopharmacology: p. 197-211.
Green, A.R., Mechan AO, Farley C, Ogilvie R, Nutt DJ, Professor David Nutt's open letter to the Advisory Council on the Misuse of Drugs regarding the classification of MDMA (ecstasy). Journal of Psychopharmacology: p. 675-686.
Freudenmann, R.W., F. Öxler, and S. Bernschneider‐Reif, The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction, 2006. 101(9): p. 1241-1245.
Pentney, A.R., An exploration of the history and controversies surrounding MDMA and MDA. Journal of psychoactive drugs, 2001. 33(3): p. 213-221.
Nuwer, R., I Feel Love: MDMA and the Quest for Connection in a Fractured World. 2023: Bloomsbury Publishing USA.
Holland, J., THE LEGAL STATUS OF MDMA. Ecstasy: The Complete Guide: A Comprehensive Look at the Risks and Benefits of MDMA, 2001: p. 146.
Mithoefer, M.C., Mithoefer, A. T., Wagner, M. T., Dawsons, K. T., McCann, U. D., & Bradshaw, R. C, 3,4-Methylenedioxymethamphetamine (MDMA)-Assisted Psychoth erapy for Treatment-Resistant Post-Traumatic Stress Disorder: Study Design and Preliminary Results. Psychotherapy and Psychosomatics. 2017: p. 102-110.
Liechti, M., Gamma, A., & Vollenweider, F. X. , The Pharmacology of MDMA: A Review. Neuropsychopharmacology, 2018.
Freedman, D.S., Moreno, F. A., & Nutt, D. J., Potential for 3,4-methylenedioxy methamphetamine (MDMA)-assisted psychotherapy for treatment-resistant depression: a narrative review of the preclinical and clinical literature. Journal of Psychoph armacology, 2020: p. 120-141.
Grob, C.S., Liechti, M., Landt, P., Phan, S. H., Leichenger, R., & Passie, T. (2018), Pilot study of MDMA-assisted psychotherapy for social anxiety in autism spectrum disorder. The Journal of Nervous and Mental Disease, 2018: p. 855-862.
Johnson, M.W., Griffiths, R. R., Hendricks, P. S., Waldman, A. T., McCann, U. D., & Nutt, D. J., Long-term follow-up of a pilot study of MDMA-assisted psychotherapy for treatment-resistant post-traumatic stress disorder. The Journal of Psychopharmacology: p. 425-436.
Lieberman, M.D., & McGlinchey, E. M., Neurobiological substrates of social anxiety disorder: a review of functional neuroimaging studies. Depression and Anxiety. a review of functional neuroimaging studies. Depression and Anxiety. 1013-1025.
Mithoefer, M.C, Mithoefer, A. T, Buchanan, J., & Moreno, F. A, 3,4-Methylenedioxym ethamphetamine (MDMA)-assisted psychotherapy for treatment-resistant post-traumatic stress disorder in older adults. . The American Journal of Geriatric Psychiatry: p.856-863.
Mithoefer, M.C., Wagner, M. T., Mithoefer, A. T., Jerome, L., & Doblin, R. , The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Journal of Psychopharmacology, 2011: p. 439-452.
Published
How to Cite
Issue
Section
Copyright (c) 2024 Amit Prasad Rath

This work is licensed under a Creative Commons Attribution 4.0 International License.